SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is advancing its next-generation GLP-1 candidate, GEP-44, through its subsidiary GlucaPharm Inc., as the global obesity and metabolic disease market expands rapidly. The company is developing a patented triple agonist peptide that targets GLP-1 and peptide YY receptors, aiming to differentiate itself through improved efficacy, tolerability, and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare. Long-term market projections for obesity drugs exceed $200 billion, according to the company.
SureNano enters an increasingly competitive GLP-1 landscape dominated by major pharmaceutical companies including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN), and Pfizer Inc. (NYSE: PFE). Industry momentum continues accelerating as these large-cap incumbents advance next-generation obesity and diabetes therapies through new formulations, expanded indications, and reduced-frequency dosing strategies aimed at improving patient access and adherence.
While large pharmaceutical companies dominate the current market with blockbuster GLP-1 products, SureNano is positioning itself as an emerging microcap participant focused on preclinical innovation, alternative delivery technologies, and broader platform opportunities that may extend beyond metabolic disease therapeutics. The company believes GEP-44's potential for non-injectable delivery could address a key barrier to patient adoption, as many patients prefer oral or other non-invasive administration methods.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP-44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026).
In addition to its pharmaceutical focus, SureNano's initial business involves the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound that provides the base for high performance nanoemulsions. The company has an exclusive license to distribute the surfactant within Canada, Oklahoma, USA, and Colorado, USA. However, the company is now developing into a pharmaceutical-focused entity through the advancement of its patented therapeutic candidate.
For more information, see the full press release at https://ibn.fm/g3EkQ. The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF.